WHO Medicines Strategy - Countries at the Core - 2004

WHO Medicines Strategy - Countries at the Core - 2004 - 2007
(2004; 163 pages)

Table of Contents

	Review process and acknowledgements
	Acronyms
	Highlights
		Expanding access to essential medicines
		The challenge of meeting essential medicine needs
		Achievements 2000-2003
		Responding to country needs
		Tracking progress
		Operational capacity
	Medicines and public health
		Current challenges in a changing world
		Hope and promise for the future
		Progress in 2000-2003
		Objectives and expected outcomes for 2004-2007
		Priorities for 2004-2007
	Components of the strategy
		Component 1. National policies on medicines
		Component 2. National policies on traditional medicine and complementary and alternative medicine
		Component 3. Sustainable financing mechanisms for medicines
		Component 4. Supplying medicines
		Component 5. Norms and standards for pharmaceuticals
		Component 6. Regulation and quality assurance of medicines
		Component 7. Using medicines rationally
	Implementing the strategy - countries at the core
		Working with countries - supporting and enabling national resources/capacity
		Working in partnership - supporters and co-workers
		Working in line with WHO Strategy - links in the knowledge chain building strength
	Monitoring progress with the strategy - measuring against indicators at country level
	References
	Endnotes

References

¹Annual report 2000, Essential Drugs and Medicines Policy. Geneva, World Health Organization, 2001 (WHO/EDM/2001.4); Annual report 2001, Essential Drugs and Medicines Policy: Extending the evidence base. Geneva, World Health Organization, 2002 (WHO/EDM/2002.1); Annual report 2002, Essential Drugs and Medicines Policy: Supporting countries to close the access gap. Geneva, World Health Organization, 2003 (WHO/EDM/2003.1).

²Essential drugs in brief. Geneva, World Health Organization. Journal issued three times per year.

³ World Health Assembly Resolutions Revised drug strategy (A53/10 and A54/17) and WHO medicines strategy (A55/12 and A56/16).

⁴How to develop and implement a national drug policy. WHO Policy Perspectives on Medicines, No.6. Geneva, World Health Organization, 2003 (WHO/EDM/2002.5).

⁵Questionnaire on country pharmaceutical situations. Geneva, World Health Organization, 2003 (EDM/DAP).

⁶Globalization, TRIPS and access to pharmaceuticals. WHO Policy Perspectives on Medicines, No. 3. Geneva, World Health Organization, 2001 (WHO/EDM/2001.2).

⁷Annual report 2002, Essential Drugs and Medicines Policy: Supporting countries to close the access gap. Geneva, World Health Organization, 2003 (WHO/EDM/2003.1).

⁸Implications of the Doha Declaration on the TRIPS Agreement and Public Health. Geneva, World Health Organization, 2002. Health Economics and Drugs, EDM Series No. 12 (WHO/EDM/PAR/2002.3).

⁹Annual report 2002. Op. cit.

¹⁰ Troullier P et al. Lancet, 2002, 359:2188-94; Pécoul B et al. Fatal imbalance. The crisis in research and development for drugs for neglected diseases. Geneva, Médecins Sans Frontièrès. 2001. (www.accessmed-msf.org); Morel CM. Parasitology Today, 2001.

¹¹Introducing the gender perspective in national essential drugs programmes. Geneva, World Health Organization, 2001 (EDM/DAP/2001.1).

¹² http://www.who.int/gender/documents/fact/en/

¹³World development report 2003. New York, United Nations Development Programme, 2003.

¹⁴Ethical criteria for medicinal drug promotion. Geneva, World Health Organization, 1988 (http://www.who.int/medicines/library/dap/ethical-criteria/ethicalen.shtml).

¹⁵ Davidoff F et al. Sponsorship, authorship and accountability. Lancet, 2001, 325:854-856 (published simultaneously in 12 other medical journals).

¹⁶ http://www.transparency.org/

¹⁷ http://www.corisweb.org/

¹⁸WHO traditional medicine strategy 2002-2005. Geneva, World Health Organization, 2002 (WHO/EDM/TRM/2002.1).

¹⁹ World Health Assembly Resolution 56.31. Traditional medicine.

²⁰Legal status of traditional medicine and complementary/alternative medicine. Geneva, World Health Organization, 2001 (WHO/EDM/TRM/2001).

²¹Global comparative pharmaceutical expenditures with related reference information. Health Economics and Drugs, EDM Series No.3. Geneva, World Health Organization, 2000 (EDM/PAR/2000.2).

²² http://www3.who.int/whosis/cmh/cmh_report/e/pdf/001-004.pdf

²³World medicines situation. Geneva, World Health Organization (In preparation).

²⁴Health reform and drug financing. Geneva, World Health Organization, 1998 (WHO/DAP/98.3).

²⁵World health report 1999: Making a difference. Geneva World Health Organization; 1999; World health report 2000; Shaping the future. Geneva World Health Organization, 2000; Public-private roles in the pharmaceutical sector. Geneva, World Health Organization, 1997 (WHO/DAP/97.12).

²⁶Global Fund to Fight Aids, Tuberculosis and Malaria (http://www.globalfundatm.org).

²⁷ World Bank HIV/AIDS (http://www1.worldbank.org/hiv_aids/index.asp).

²⁸World health report 1999: Making a difference. Geneva, World Health Organization, 1999.

²⁹What is WHO doing to improve drug price information? WHO Fact Sheet: Drug Price Information Services. (http://www.who.int/medicines/organization/par/ipc/drugpriceinfo.shtml).

³⁰Medicine prices: a new approach to measurement. Geneva, World Health Organization and Health Action International, 2003 (WHO/EDM/PAR/2003.2).

³¹The use of essential drugs Report of the WHO Expert Committee 1997 (including the 10^th Model List of Essential Medicines). Geneva, World Health Organization, 1998 (WHO Technical Report Series No. 882).

³²World pharmaceutical situation survey 1999. World Health Organization. EDM/DAP.

³³ Quick JD. Editorial. Essential medicines twenty-five years on: closing the access gap. Health Policy and Planning 2003;18(i):1-3.

³⁴Guidelines for drug donations. 2nd ed. Interagency guidelines. Geneva, World Health Organization, 1999 (WHO/EDM/PAR/99.2).

³⁵Guidelines for price discounts of single-source pharmaceuticals. Geneva, World Health Organization, 2003 (WHO/EDM/PAR/2003.3).

³⁶How to develop and implement a national drug policy, 2nd ed. Geneva, World Health Organization, 2001.

³⁷ Quick JD et al (eds). Managing drug supply. 2nd ed. West Hartford, Connecticut, Kumarian Press, 1997.

³⁸ Kaplan WA, Laing R. Is local production of pharmaceuticals a way to improve pharmaceutical access in developing and transitional countries? Setting a research agenda.. Unpublished document. Boston University School of Public Health (http://dcc2.bumc.bu.edu/richardl/RPM+_Project/local_production.htm).

³⁹Operational principles for good pharmaceutical procurement. Interagency guidelines. Geneva, World Health Organization, 1999 (WHO/EDM/PAR/99.5).

⁴⁰ Quick JD et al (eds). Part III, Section B, Procurement. In: Managing drug supply. 2nd ed. West Hartford, Connecticut, Kumarian Press, 1997.

⁴¹Surmounting challenges: procurement of antiretroviral medicines in low- and middle-Income countries. Geneva, World Health Organization, Médecins Sans Frontières and Joint United Nations Programme on HIV/AIDS, 2003.

⁴²The impact of implementation of ICH guidelines in non-ICH countries. Report of a WHO Meeting. Geneva, 13-15 September 2001. Geneva, World Health Organization, 2002. Regulatory Support Series, No.9 (WHO/EDM/QSM/2002.3).

⁴³Quality assurance of pharmaceuticals - A compendium of guidelines and related materials, Vol 1, Geneva, World Health Organization, 1997. Vol 2. Geneva, World Health Organization, 1999.

⁴⁴ WHO Expert Committee on Specifications for Pharmaceutical Preparations, 38th Report. Geneva, World Health Organization 2004 (Technical Report Series No. 908).

⁴⁵The international pharmacopoeia, 3rd ed., Vol. 1-5. Geneva, World Health Organization, 2003.

⁴⁶Guidelines for the WHO review of dependence-producing psychoactive substances for international control. Geneva, World Health Organization, 2000 (WHO/EDM/QSM/2000.5).

⁴⁷Achieving balance in national opioids control policy: Guidelines for assessment. Geneva, World Health Organization, 2000 (WHO/EDM/QSM/2000.4).

⁴⁸Report of the International Narcotics Control Board for 2002. Vienna, United Nations, 2002 (E/INCB/2002/1).

⁴⁹Effective drug regulation: what can countries do? Theme paper for discussion. Geneva, World Health Organization, 1999 (WHO/HTP/EDM/Mac (11)99.6).

⁵⁰Annual report 2001 - Essential Drugs and Medicines Policy: Extending the evidence base. Geneva, World Health Organization, 2002.

⁵¹ ibid.

⁵²Effective medicines regulation: ensuring safety, efficacy and quality. Geneva, WHO Policy Perspectives on Medicines, No.7. Geneva, World Health Organization, 2003 (WHO/EDM/2003.2).

⁵³ Reggi V et al. Prescribing information in 26 countries: a comparative study. European Journal of Clinical Pharmacology, Aug 2003; 59(4):263-70.

⁵⁴ Ratanwijitrasin S, Wondemagegnehu E. Effective drug regulation - A multicountry study, and Annex 1: Guide for data collection to assess drug regulatory performance. Geneva, World Health Organization, 2002.

⁵⁵ Quick JD. Ensuring access to essential medicines in developing countries - A framework for action. Geneva, World Health Organization. Presentation at the 25th Anniversary of Essential Medicines Seminar, Geneva, 21 October 2002.

⁵⁶The selection and use of essential medicines. Report of the WHO Expert Committee 2002 (including the 12^th Model List of Essential Medicines). Geneva, World Health Organization (WHO Technical Report Series No. 914).

⁵⁷Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003. (http://www.who.int/chronic_conditions/adherencereport/en/).

⁵⁸The selection and use of essential medicines. Report of the WHO Expert Committee 2002 (including the 12th Model List of Essential Medicines). Geneva, World Health Organization, 2003 (WHO Technical Report Series No. 914).

⁵⁹WHO Model Formulary 2002. Geneva, World Health Organization, 2002.

⁶⁰ WHO/EDM medicines website: http://www.who.int/medicines/

⁶¹ Rosenthal MB et al. Promotion of prescription drugs to consumers. New England Journal of Medicine, 2002, 346:498-505.

⁶² New WHO/NGO database on drug promotion launched. Essential Drugs Monitor, 2002, 31:18.

⁶³Ethical criteria for medicinal drug promotion. Geneva, World Health Organization,1988.

⁶⁴ Hogerzeil H. Promoting rational prescribing. British Journal of Clinical Pharmacology, 1995;39:1-6.

⁶⁵ Quick JD et al., eds. Chapter 29 Investigating drug use. In: Managing drug supply, 2nd ed. West Hartford, Connecticut, Kumarian Press, 1997 (page 437).

⁶⁶ WHA51.17 (1998) World Health Assembly Resolution. Emerging and other communicable diseases: antimicrobial resistance; WHA54.14 (2001) World Health Assembly Resolution. Strengthening health systems in developing countries; EM/RC49/R.10 (2002) WHO Regional Committee for the Eastern Mediterranean Region. Antimicrobial resistance and rational use of antimicrobial agents; WPR/RC53.R5 (2002) WHO Regional Committee for the Western Pacific Region. Antimicrobial resistance.

⁶⁷WHO Global strategy for containment of antimicrobial resistance. Geneva, World Health Organization, 2001 (WHO/CDS/CSR/DRS/2001.2).

⁶⁸Pharmaceuticals and health sector reform in the Americas: an economic perspective. Washington DC, World Health Organization and Pan American Health Organization, 1998.

⁶⁹Promoting rational use of medicines. WHO Policy Perspectives on Medicine, No. 5. Geneva, World Health Organization, 2002 (WHO/EDM/2002.3).

⁷⁰Annual report 2002. Op. cit.